IP Library Granted Patent US 8,871,879
Granted Patent B2
US 8,871,879 · App. 13/779,190 · Granted Oct 28, 2014

Latent, high-activity olefin metathesis catalysts containing an N-heterocyclic carbene ligand

Inventors: Thay Ung (Los Angeles, CA); Yann Schrodi (Pasadena, CA); Mark S. Trimmer (Monrovia, CA); Andrew Hejl (Pasadena, CA); Daniel Sanders (Pasadena, CA); Robert H. Grubbs (South Pasadena, CA)
Assignees: Materia, Inc.; California Institute of Technology
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,871,879
App. No.
13/779,190
Granted
Oct 28, 2014
Kind
B2
Abstract

The invention provides novel organometallic complexes useful as olefin metathesis catalysts. The complexes have an N-heterocyclic carbene ligand and a chelating carbene ligand associated with a Group 8 transition metal center. The molecular structure of the complexes can be altered so as to provide a substantial latency period. The complexes are particularly useful in catalyzing ring closing metathesis of acyclic olefins and ring opening metathesis polymerization of cyclic olefins.

Claims (62)

1. A complex having the structure of formula (I)

wherein:

α and β represent single bonds or unsaturated bonds, with the proviso that α and β cannot both be unsaturated bonds;

M is a Group 8 transition metal;

R 1 and R 2 are independently selected from hydrogen, hydrocarbyl, substituted hydrocarbyl, heteroatom-containing hydrocarbyl, substituted heteroatom-containing hydrocarbyl, and functional groups;

Q is an organic diradical;

X 1 and X 2 are cis anionic ligands, and may be the same or different;

L 1 is a neutral electron donor ligand, and p is zero or 1;

when α is a single bond, L 2 is selected from NR 7 R 8 , PR 7 R 8 , N═CR 7 R 8 , and R 7 C═NR 8 , where R 7 and R 8 are independently selected from substituted and/or heteroatom-containing C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl, and C 5 -C 24 aryl, or R 7 and R 8 can be taken together to form a heterocyclic ring;

when α is an unsaturated bond, L 2 is selected from NR 7 and PR 7 , where R 7 is as defined previously, or L 2 and Z represent adjacent atoms in an aromatic ring;

Y and Z are linkages independently selected from hydrocarbylene, substituted hydrocarbylene, heteroatom-containing hydrocarbylene, substituted heteroatom-containing hydrocarbylene, —O—, —S—, —NR 9 , and —PR 9 —, wherein R 9 is selected from hydrocarbyl, substituted hydrocarbyl, heteroatom-containing hydrocarbyl, and substituted heteroatom-containing hydrocarbyl, and further wherein Y and Z may represent adjacent atoms in an aromatic ring;

m is zero or 1;

n is zero or 1; and

wherein the complex is a positional isomer, wherein L 2 and the ligand containing Q are bonded to M in a cis orientation.

2. A complex of claim 1 having the structure of formula (II)

wherein:

β represents a single bond or an unsaturated bond;

M is a Group 8 transition metal;

R 1 and R 2 are independently selected from hydrogen, hydrocarbyl, substituted hydrocarbyl, heteroatom-containing hydrocarbyl, substituted heteroatom-containing hydrocarbyl, and functional groups;

Q is an organic diradical;

X 1 and X 2 are cis anionic ligands, and may be the same or different;

L 1 is a neutral electron donor ligand, and p is zero or 1;

R 7 and R 8 are independently selected from substituted and/or heteroatom-containing C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl, and C 5 -C 24 aryl, or R 7 and R 8 can be taken together to form a heterocyclic ring;

Y and Z are linkages independently selected from hydrocarbylene, substituted hydrocarbylene, heteroatom-containing hydrocarbylene, substituted heteroatom-containing hydrocarbylene, —O—, —S—, —NR 9 , and —PR 9 —, wherein R 9 is selected from hydrocarbyl, substituted hydrocarbyl, heteroatom-containing hydrocarbyl, and substituted heteroatom-containing hydrocarbyl, and further wherein Y and Z may represent adjacent atoms in an aromatic ring; and

wherein the complex is a positional isomer, wherein NR 7 R 8 and the ligand containing Q are bonded to M in a cis orientation.

3. The complex of claim 2 , wherein R 7 and R 8 are C 1 -C 12 alkyl or C 5 -C 12 aryl, and Y is a substituted or unsubstituted methylene or ethylene linkage.

4. A complex of claim 1 having the structure of formula (III)

wherein:

β represents a single bond or an unsaturated bond;

M is a Group 8 transition metal;

R 1 and R 2 are independently selected from hydrogen, hydrocarbyl, substituted hydrocarbyl, heteroatom-containing hydrocarbyl, substituted heteroatom-containing hydrocarbyl, and functional groups;

Q is an organic diradical;

X 1 and X 2 are cis anionic ligands, and may be the same or different;

L 1 is a neutral electron donor ligand, and p is zero or 1;

R 7 and R 8 are independently selected from substituted and/or heteroatom-containing C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl, and C 5 -C 24 aryl, or R 7 and R 8 can be taken together to form a heterocyclic ring;

Y and Z are linkages independently selected from hydrocarbylene, substituted hydrocarbylene, heteroatom-containing hydrocarbylene, substituted heteroatom-containing hydrocarbylene, —O—, —S—, —NR 9 , and —PR 9 —, wherein R 9 is selected from hydrocarbyl, substituted hydrocarbyl, heteroatom-containing hydrocarbyl, and substituted heteroatom-containing hydrocarbyl, and further wherein Y and Z may represent adjacent atoms in an aromatic ring; and

wherein the complex is a positional isomer, wherein PR 7 R 8 and the ligand containing Q are bonded to M in a cis orientation.

5. The complex of claim 4 , wherein R 7 and R 8 are C 1 -C 12 alkyl or C 5 -C 12 aryl, and Y is a substituted or unsubstituted methylene or ethylene linkage.

6. The complex of claim 5 , wherein R 7 and R 8 are phenyl and Y is ethylene.

7. A complex of claim 1 having the structure of formula (IV)

wherein:

M is a Group 8 transition metal;

R 1 and R 2 are independently selected from hydrogen, hydrocarbyl, substituted hydrocarbyl, heteroatom-containing hydrocarbyl, substituted heteroatom-containing hydrocarbyl, and functional groups;

Q is an organic diradical;

X 1 and X 2 are cis anionic ligands, and may be the same or different;

L 1 is a neutral electron donor ligand, and p is zero or 1;

Y is a linkage selected from hydrocarbylene, substituted hydrocarbylene, heteroatom-containing hydrocarbylene, substituted heteroatom-containing hydrocarbylene, —O—, —S—, —NR 9 , and —PR 9 —, wherein R 9 is selected from hydrocarbyl, substituted hydrocarhyl, heteroatom-containing hydrocarbyl, and substituted heteroatom-containing hydrocarbyl; and wherein the complex is a positional isomer having a pyridine ligand, wherein the pyridine ligand and the ligand containing Q are bonded to M in a cis orientation.

8. A complex of claim 1 having the structure of formula (V)

wherein:

M is a Group 8 transition metal;

R 1 and R 2 are independently selected from hydrogen, hydrocarbyl, substituted hydrocarbyl, heteroatom-containing hydrocarbyl, substituted heteroatom-containing hydrocarbyl, and functional groups;

Q is an organic diradical;

X 1 and X 2 are cis anionic ligands, and may be the same or different;

L 1 is a neutral electron donor ligand, and p is zero or 1; and

R 7 is selected front substituted and/or heteroatom-containing C 1 -C 20 alkyl, C 2 -C 20 alkenyl,C 2 -C 20 alkynyl, and C 5 -C 24 aryl;

Y and Z are linkages independently selected from hydrocarbylene, substituted hydrocarbylene, heteroatom-containing hydrocarbylene, substituted heteroatom-containing hydrocarbylene, —O—, —S—, —NR 9 , and —PR 9 —, wherein R 9 is selected from hydrocarbyl, substituted hydrocarbyl, heteroatom-containing hydrocarbyl, and substituted heteroatom-containing hydrocarbyl; and

wherein the complex is a positional isomer, wherein NR 7 and the ligand containing Q are bonded to M in a cis orientation.

9. A method for catalyzing an olefin metathesis reaction, comprising contacting an olefinic reactant with the complex of claim 1 under reaction conditions selected to enable olefin metathesis.

10. The complex of claim 1 , wherein the complex has the structure

11. A method for controlling the reaction latency period of an olefin metathesis reaction, comprising combining an olefin metathesis reaction mixture with a complex of claim 1 under reaction conditions selected to enable olefin metathesis.

12. The method of claim 11 , wherein the organometallic complex exhibits a latency period when combined with the olefin metathesis reaction mixture.

13. The method of claim 12 , wherein the latency period is at least two minutes.

Assignments (1)
CONFIRMATORY LICENSE Recorded Aug 13, 2013
From: CALIFORNIA INSTITUTE OF TECHNOLOGY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 031004/0812 →
Continuity (4)
Continuation 11094102 · Mar 29, 2005
Provisional Application 60557742 · Mar 29, 2004
Provisional Application 60604158 · Aug 23, 2004
Related Publication 20130296511A1 · Nov 7, 2013